Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 21 (4), 409-419

An Update on DPP-4 Inhibitors in the Management of Type 2 Diabetes

Affiliations
Review

An Update on DPP-4 Inhibitors in the Management of Type 2 Diabetes

Avivit Cahn et al. Expert Opin Emerg Drugs.

Abstract

DPP-4 inhibitors are a class of compounds used for the treatment of type 2 diabetes. The drugs inhibit the degradation of GLP-1, thus amplifying the incretin effect. They have moderate glycemic efficacy, a low propensity of causing hypoglycaemia and are weight neutral. The drugs are often used as second line therapy after metformin. Areas covered: This review summarizes the available compounds in the market and discusses the novel compounds that are currently under development. Several large cardiovascular outcome trials with some of the compounds have been completed, and their results and implications are considered. Fixed dose combination pills are currently the main focus of research and the contribution of these to the care of patients with diabetes is further discussed. Expert opinion: The DPP-4 inhibitors have been a successful class in drug development for diabetes. Taken orally and available as fixed dose combinations with metformin or with SGLT-2 inhibitors, they have reached a large market share of over 7 billion dollars. Other than retagliptin, it does not appear that any additional compound will be launched soon. Currently, the main focus is on the development of additional fixed dose combinations with SGLT-2 inhibitors, but the success of these combinations remains to be seen.

Keywords: DPP-4 inhibitors; alogliptin; anagliptin; combination pills; evogliptin; gemigliptin; gosogliptin; linagliptin; omarigliptin; outcome studies; retagliptin; saxagliptin; sitagliptin; teneligliptin; trelagliptin; vildagliptin.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms

Feedback